Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs

J Hosp Infect. 2013 Jun;84(2):132-7. doi: 10.1016/j.jhin.2013.02.015. Epub 2013 Apr 19.

Abstract

Background: Meticillin-resistant Staphylococcus aureus (MRSA) infections increase hospital costs primarily by prolonging patient length of stay (LOS).

Aim: To estimate the health-economic burden of MRSA infections at a Swiss University hospital using different analytical approaches.

Methods: Excess LOS was estimated by: (i) multistate modelling comparing MRSA-infected and MRSA-free patients with MRSA infection as time-dependent exposure; (ii) matching MRSA-infected patients with a cohort of MRSA-uninfected patients. The economic impact was assessed by: (i) comparing cost estimates between MRSA-infected and MRSA-free patients and multiplying excess LOS by bed-day cost; (ii) comparing real costs between MRSA-infected and MRSA-colonized non-infected patients.

Findings: The crude mean LOS was 37.3, 33.0 and 8.8 days for MRSA-infected, MRSA-colonized and MRSA-free patients, respectively. Excess LOS attributable to MRSA infection was 11.5 [95% confidence interval (CI): 7.9-15] or 15.3 days according to multistate modelling and matched analysis, respectively. The likelihood of discharge after MRSA infection was significantly reduced (adjusted hazard ratio: 0.69; 95% CI: 0.59-0.81). Average bed-day costs for MRSA-infected patients were 1.49- and 1.26-fold higher than for the general population hospitalized in acute wards and MRSA-colonized patients, respectively. MRSA infection resulted in an average additional cost of about 800 Swiss francs per day.

Conclusions: This analysis emphasizes the financial impact of MRSA infections, demonstrates the importance of accounting for time-dependent bias and confirms that multistate modelling is a valid strategy for estimating excess LOS and costs after MRSA infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Cross Infection / economics*
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Female
  • Health Care Costs / statistics & numerical data*
  • Hospitals, University
  • Humans
  • Length of Stay / statistics & numerical data*
  • Male
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification*
  • Middle Aged
  • Staphylococcal Infections / economics
  • Staphylococcal Infections / epidemiology*
  • Staphylococcal Infections / microbiology
  • Switzerland / epidemiology